Last reviewed · How we verify

NCT00501878

2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides

Completed Phase 4 Last updated 7 March 2012
What this trial tests

Phase 4 trial testing 2.5% or 10% phenylephrine in Diabetes Mellitus in 100 participants. Completed in 1 July 2007.

Timeline
1 May 2007
1 July 2007

Quick facts

Lead sponsorKhon Kaen University
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposediagnostic
Enrollment100
Start date1 May 2007
Estimated completion1 July 2007
Sites1 location across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Khon Kaen University

Who can join

Adults 18 to 70, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

To compare the clinical efficacy and systemic side effects between 2.5% and 10% phenylephrine for mydriasis in diabetic patient with darkly pigmented irides.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other Khon Kaen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00501878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing